Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

LongLongStock Jun. 29 at 8:12 AM

$CAPR i think the FDA just want to outsource their decision via ad-com

0 · Reply

HarryPopotter Jun. 29 at 6:55 AM

$CAPR @TheWolfOfOmaha But from a regulator’s perspective, the likely “issues” are not about whether the trial succeeded statistically, they’re about: *strengt of evidence vs FDA approval standard * durability and reproducibility * reliance on small datasets * endpoint clinical meaning * manufacturing robustness (CMC) * whether HOPE-3 is truly confirmatory

1 · Reply

TheWolfOfOmaha Jun. 29 at 5:54 AM

$CAPR ”We have a randomized double blind placebo control trial. We hit the primary endpoint, we hit the secondary endpoints,” Marbán said. “I don’t know what their issues would be.”

0 · Reply

HarryPopotter Jun. 29 at 4:42 AM

$CAPR The FDA briefing document will likely be the most important catalyst before the AdCom. It usually explains exactly what questions the FDA wants the committee to address and provides valuable insight into the agency’s view of the data. If the briefing document is generally positive and focuses on the strength of the overall evidence rather than questioning whether HOPE-3 demonstrated efficacy, that would likely be an encouraging sign heading into the meeting.

1 · Reply

Heroforest Jun. 29 at 4:27 AM

$CAPR which one of you sold $20 puts and bought 30 calls in millions expiring in August

0 · Reply

HamBoneXoXo Jun. 29 at 3:19 AM

$CAPR Always wondered where Binks is, the company CMO. Yet to hear him say much about deramio.

0 · Reply

HamBoneXoXo Jun. 29 at 3:14 AM

$CAPR Ph3 is too borderline to be considered "substantial proof" and forget about ph2 data which fda called junk and all is left is 9 patients in the ph2 ole, way too small to be of significance. The voting members will see through the data mining, sub grouping, selective mri, and the so so p values and very likely return a 60/40 no vote. I can’t think of any medical or clinical or life style change that is profound enough to encourage a strong or majority Yes on the part of the panel of experts.

2 · Reply

SoYeonPicks Jun. 29 at 3:03 AM

I remember stumbling upon $SLS last year when it was under 2 (saw it over on the $CAPR board at that time but don't remember who brought it up.. and yes, I'm still holding CAPR too) and after reading the DD and doing my own research, I was so ecstatic that I sold off some of my other positions at that time (GOOG, BABA, etc) immediately to buy this. When it spiked up to 3 on the 72nd event, I took whatever money I had left and added another 5k shares. Now it's 2026 and the SP keeps going up, but I'm not selling because my thesis and conviction have only gotten stronger. I truly believe this company will change AML care and beyond and will make its mark on history, and I'm grateful to be along for the journey. I will now enjoy my morning coffee, relax, do some work, and let the science validate what we have believed all along 😇

6 · Reply

dnfrs Jun. 29 at 2:05 AM

$CAPR The more I think about it, the more I think the FDA is scheduling a lot of ADCOM's to show that they have moved on from the Makary/Prasad era! * Linda will be outstanding at the ADCOM. * The DMD community will be great. * Key Opinion Leaders get a voice. * The 5 year data can be presented. AND THE FDA get to show they have moved on from the Makary/Prasad show! Win. Win. Win.

2 · Reply

My_Lai_1968 Jun. 29 at 1:57 AM

$CAPR I feel very strongly that Capricor shouldn't even attend the Adcom Conference. They could purchase television ads, radio ads and magazine ads anytime they choose to. Also, I'm sure that they own quite a few printers in their offices and could create their own ads if they wished to. Linda should just come up with an excuse to tell the people at Adcom that they will not be attending such a frivolous meeting.

1 · Reply

Capricor announces FDA advisory committee meeting to review Deramiocel BLA

Jun 26, 2026, 10:02 AM EDT - 2 days ago

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

2026-06-26T13:30:37.000Z - 2 days ago

Capricor presents five-year data from HOPE-2 open-label extension study

Jun 26, 2026, 9:05 AM EDT - 2 days ago

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Jun 19, 2026, 5:47 PM EDT - 9 days ago

Caprock Announces Closing of Private Placement

Jun 17, 2026, 4:32 PM EDT - 11 days ago

Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.

2026-06-16T18:45:26.000Z - 12 days ago

Capricor Therapeutics management to meet with Oppenheimer

Jun 12, 2026, 6:02 PM EDT - 16 days ago

Caprock Announces Proposed Private Placement

Jun 12, 2026, 5:40 PM EDT - 16 days ago

Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m

Jun 10, 2026, 10:00 AM EDT - 18 days ago

Capricor Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 9:25 AM EDT - 20 days ago

Capricor Therapeutics to Present at Upcoming Investor Conferences

May 29, 2026, 7:00 AM EDT - 4 weeks ago

Capricor Therapeutics Slides: Corporate presentation

2026-05-15T02:55:10.000Z - 6 weeks ago

Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital

May 12, 2026, 4:30 PM EDT - 6 weeks ago

Capricor Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 6 weeks ago

Capricor Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 6 weeks ago

Capricor Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:05 PM EDT - 6 weeks ago

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-05-08T18:58:25.000Z - 7 weeks ago

Capricor files suit against NS Pharma over Deramiocel distribution deal

May 4, 2026, 4:05 PM EDT - 7 weeks ago

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

Apr 10, 2026, 8:00 AM EDT - 2 months ago

Capricor Therapeutics Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Capricor Therapeutics Proxy statement: Proxy filing

2026-03-20T12:45:14.000Z - 3 months ago

Capricor Therapeutics price target raised to $43 from $41 at Roth Capital

2026-03-13T18:35:53.000Z - 3 months ago

Capricor selloff today a buying opportunity, says Roth Capital

2026-03-13T16:01:07.000Z - 3 months ago

Capricor Therapeutics price target raised to $51 from $48 at Alliance Global

2026-03-13T12:27:39.000Z - 3 months ago

Capricor Therapeutics price target raised to $63 from $50 at B. Riley

2026-03-13T12:02:13.000Z - 3 months ago

Capricor Therapeutics price target raised to $58 from $45 at Piper Sandler

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Capricor Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Capricor Therapeutics Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 3 months ago

Capricor Therapeutics Earnings release: Q4 2025

2026-03-12T20:16:10.000Z - 3 months ago

Capricor Therapeutics reports Q4 EPS (62c), consensus (55c)

Mar 12, 2026, 4:01 PM EDT - 3 months ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

2026-03-12T13:15:17.000Z - 3 months ago

Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial

Mar 12, 2026, 9:00 AM EDT - 3 months ago

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

2026-03-10T13:38:59.000Z - 3 months ago

Capricor announces establishment of new PDUFA date for dermiocel BLA

Mar 10, 2026, 9:25 AM EDT - 3 months ago

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Dec 17, 2025, 1:00 PM EST - 6 months ago

Capricor Therapeutics Transcript: Study Result

Dec 4, 2025, 4:01 PM EST - 7 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Dec 3, 2025, 11:30 AM EST - 7 months ago

Capricor Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 7 months ago

Capricor Therapeutics Transcript: Status Update

Dec 3, 2025, 8:00 AM EST - 7 months ago

Capricor Therapeutics Press release: Status Update

Dec 3, 2025, 8:00 AM EST - 7 months ago

Capricor Therapeutics Slides: Status Update

Dec 3, 2025, 7:44 AM EST - 7 months ago

Capricor's muscle disorder cell therapy succeeds in late-stage study

Nov 10, 2025, 4:30 PM EST - 8 months ago

Capricor Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Capricor Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 8 months ago

Capricor Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 9:15 AM EST - 8 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Oct 31, 2025, 9:15 AM EDT - 8 months ago

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Oct 13, 2025, 7:00 AM EDT - 9 months ago

Capricor Therapeutics Slides: Corporate Presentation

Oct 3, 2025, 10:45 AM EDT - 9 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Capricor Therapeutics Transcript: Study Update

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Capricor Therapeutics Press release: Study Update

Sep 25, 2025, 7:15 AM EDT - 9 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 10, 2025, 8:00 AM EDT - 10 months ago

Capricor Therapeutics Registration statement: Registration Filing

Sep 9, 2025, 9:20 AM EDT - 10 months ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 11, 2025, 4:30 PM EDT - 11 months ago

Capricor Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 11 months ago

Capricor Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 11 months ago

Capricor Therapeutics Earnings release: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 11 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 11 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 14, 2025, 4:14 PM EDT - 1 year ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 11, 2025, 4:53 PM EDT - 1 year ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

LongLongStock Jun. 29 at 8:12 AM

$CAPR i think the FDA just want to outsource their decision via ad-com

0 · Reply

HarryPopotter Jun. 29 at 6:55 AM

1 · Reply

TheWolfOfOmaha Jun. 29 at 5:54 AM

$CAPR ”We have a randomized double blind placebo control trial. We hit the primary endpoint, we hit the secondary endpoints,” Marbán said. “I don’t know what their issues would be.”

0 · Reply

HarryPopotter Jun. 29 at 4:42 AM

1 · Reply

Heroforest Jun. 29 at 4:27 AM

$CAPR which one of you sold $20 puts and bought 30 calls in millions expiring in August

0 · Reply

HamBoneXoXo Jun. 29 at 3:19 AM

$CAPR Always wondered where Binks is, the company CMO. Yet to hear him say much about deramio.

0 · Reply

HamBoneXoXo Jun. 29 at 3:14 AM

2 · Reply

SoYeonPicks Jun. 29 at 3:03 AM

6 · Reply

dnfrs Jun. 29 at 2:05 AM

2 · Reply

My_Lai_1968 Jun. 29 at 1:57 AM

1 · Reply

Dahlia2018 Jun. 29 at 1:57 AM

$CAPR

0 · Reply

quickaspeter Jun. 29 at 1:32 AM

$CAPR Patience, the big one is coming…💥🚀💰💰💰

0 · Reply

Macme Jun. 29 at 1:29 AM

$CAPR 4 weeks more.

0 · Reply

LongLongStock Jun. 29 at 1:21 AM

$CAPR there is a good chance this will set me up for retirement!

2 · Reply

Gain_With_Me Jun. 29 at 12:39 AM

$CAPR rebound tomorrow or deeper fall?

0 · Reply

jjkc Jun. 29 at 12:24 AM

$CAPR What was CAPR/Linda’s response to the Adcom news at the DMD meeting ?

1 · Reply

Galaxy123 Jun. 28 at 11:29 PM

$CAPR in general how early are the sponsors notified about the scheduling of an adcom ?. In our case it is just 5 weeks and also Capricor has to prepare a response document once FDA shares the briefing documentation. Reviewers then do get the documentation from Capricor and FDA for them to review and prepare for the adcom. Can those familiar with the adcom process, comment on whether it is standard practice to schedule an adcom with just 5 weeks of notice ?.

2 · Reply

Thaigrlsrk Jun. 28 at 11:25 PM

$CAPR One thing that s good to remember about approvals, you have not seen all the data you never do. FDA does. If CAPR has been truthfull deramiocel gets approved . The number one thing going for investors IMO is the trial doc's think it works. They see the kids FDA doesn't.

2 · Reply

BBMan2019 Jun. 28 at 11:05 PM

$CAPR When FDA releases the briefing documents a few days before ADcom on 29th, we will all have more clarity on the FDA's review teams thinking on Deramiocel and the reason behind the Adcom...we will likly see a move up when this happens.

2 · Reply

UncleB13 Jun. 28 at 10:31 PM

$CAPR we need the peer reviewed journal to drop in either lancet or NEJM to shut the shorts the hell up. Would be amazing to have it drop in July right before the adcom hearing.

1 · Reply

Atmwireless Jun. 28 at 9:33 PM

$CAPR WHEN we pass adcom… what do you think share price will be. My guess is we go from 26-30 to 50-60$ Then with approval we are mostly priced in but see $70

1 · Reply

nnblV2 Jun. 28 at 9:20 PM

$CAPR Honesty dont know why some are petrified of ADCOM. An overwhelming vote of confidence will blow up the stock price

3 · Reply

Market Cap	1.53B
Revenue (ttm)	0.00
Net Income (ttm)	-105.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,489,400
Avg Vol	1,115,942
Day's Range	N/A - N/A
Shares Out	57.91M
Stochastic %K	16%
Beta	0.39
Analysts	Strong Sell
Price Target	$54.11